Insulin's discovery: New insights on its ninetieth birthday

Laboratory of Diabetes and Metabolic Disorders, Feinstein Institute for Medical Research, North Shore-Long Island Jewish Health System, NY, USA. .
Diabetes/Metabolism Research and Reviews (Impact Factor: 3.55). 05/2012; 28(4):293-304. DOI: 10.1002/dmrr.2300
Source: PubMed


2012 marks the 90th year since the purification of insulin and the miraculous rescue from death of youngsters with type 1 diabetes. In this review, we highlight several previously unappreciated or unknown events surrounding the discovery. (i) We remind readers of the essential contributions of each of the four discoverers--Banting, Macleod, Collip, and Best. (ii) Banting and Best (each with his own inner circle) worked not only to accrue credit for himself but also to minimize credit to the other discoverers. (iii) Banting at the time of the insulin research was very likely suffering from post-traumatic stress disorder (PTSD) that originated during his heroic service as a surgeon in World War I on the Western Front in 1918, including an infected shrapnel wound that threatened amputation of his arm. His war record along with the newly discovered evidence of a suicide threat goes along with his paranoia, combativeness, alcohol excess, and depression, symptoms we associate with PTSD. (iv) Banting's eureka idea, ligation of the pancreatic duct to preserve the islets, while it energized the early research, was unnecessary and was bypassed early. (v) Post discovery, Macleod uncovered many features of insulin action that he summarized in his 1925 Nobel Lecture. Macleod closed by raising the question--what is the mechanism of insulin action in the body?--a challenge that attracted many talented investigators but remained unanswered until the latter third of the 20th century.

45 Reads
  • Source
    • "It is just over 90 years since J.J.R. Macleod and his team at the University of Toronto discovered insulin.1 The first patient, Leonard Thompson, at the time of treatment was on a starvation diet that was intended to extend his life for a few years. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cell therapy in the form of human islet transplantation has been a successful form of treatment for patients with type 1 diabetes for over 10 years, but is significantly limited by lack of suitable donor material. A replenishable supply of insulin-producing cells has the potential to address this problem; however to date success has been limited to a few preclinical studies.Two of the most promising strategies include differentiation of embryonic stem cells and induced pluripotent stem cells towards insulin producing cells and transdifferentiation of acinar or other closely related cell types towards β-cells. Here we discuss recent progress and challenges that need to be overcome in taking cell therapy to the clinic.
    QJM: monthly journal of the Association of Physicians 01/2014; 107(4). DOI:10.1093/qjmed/hcu025 · 2.50 Impact Factor
  • Source
    • "Historically, the causal mechanisms underlying the behavior of closed-loop systems in physiology have been identified via ingenious methods for isolating components within the integrated system, that is methods for " opening the loop. " A classic example of this is the discovery of insulin by Dr. Frederick Banting and Charles Best in 1921 and it's role in connecting food intake to substrate metabolism (Roth et al., 2012). In this case, the biological cues – insulin and glucagon – that facilitate communication between components – endocrine pancreas, liver, and muscle – can be easily assayed in the blood. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The challenges associated with demonstrating a durable response using molecular-targeted therapies in cancer has sparked a renewed interest in viewing cancer from an evolutionary perspective. Evolutionary processes have three common traits: heterogeneity, dynamics, and a selective fitness landscape. Mutagens randomly alter the genome of host cells creating a population of cells that contain different somatic mutations. This genomic rearrangement perturbs cellular homeostasis through changing how cells interact with their tissue microenvironment. To counterbalance the ability of mutated cells to outcompete for limited resources, control structures are encoded within the cell and within the organ system, such as innate and adaptive immunity, to restore cellular homeostasis. These control structures shape the selective fitness landscape and determine whether a cell that harbors particular somatic mutations is retained or eliminated from a cell population. While next-generation sequencing has revealed the complexity and heterogeneity of oncogenic transformation, understanding the dynamics of oncogenesis and how cancer cells alter the selective fitness landscape remain unclear. In this technology review, we will summarize how recent advances in technology have impacted our understanding of these three attributes of cancer as an evolutionary process. In particular, we will focus on how advances in genome sequencing have enabled quantifying cellular heterogeneity, advances in computational power have enabled explicit testing of postulated intra- and intercellular control structures against the available data using simulation, and advances in proteomics have enabled identifying novel mechanisms of cellular cross-talk that cancer cells use to alter the fitness landscape.
    Frontiers in Oncology 01/2012; 2:202. DOI:10.3389/fonc.2012.00202
  • [Show abstract] [Hide abstract]
    ABSTRACT: After the discovery of insulin in the last century, rapidly efforts were undertaken to prolong the duration of action of injected insulin, in a naïve attempt to achieve physiological insulin profiles by just one injection of insulin a day [1]. However, the insulin profile achieved by beta-cells is quite different from a continuous supply of insulin. Indeed, when reflecting on the gold standard in insulin therapy, the beta-cell itself, one can distinguish between on the one hand the small amounts of insulin being produced almost continuously aimed at keeping anabolism going and on the other hand the peaks of insulin released at moments where meals are entering the system. The main target organ for both the basal and the bolus insulin secretion of the beta-cell is the liver, with a substantial first pass effect. The major asset of the insulin secretion of the beta-cell is that it is glucose-sensitive and thus, in periods without meals, no peaks of insulin release will occur, but more importantly, when metabolism needs to switch to catabolism, also the basal secretion will diminish and shut down, allowing gluconeogenesis and glycogenolysis in liver to occur.
    Diabetes research and clinical practice 12/2012; 100(2). DOI:10.1016/j.diabres.2012.11.010 · 2.54 Impact Factor
Show more